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Abstract
Uridine, a pyrimidine nucleoside essential for the synthesis of RNA and bio-membranes, is a crucial element in the regulation of normal
physiological processes as well as pathological states. The biological effects of uridine have been associated with the regulation of the cardio-
circulatory system, at the reproduction level, with both peripheral and central nervous system modulation and with the functionality of the
respiratory system. Furthermore, uridine plays a role at the clinical level in modulating the cytotoxic effects of fluoropyrimidines in both
normal and neoplastic tissues. The concentration of uridine in plasma and tissues is tightly regulated by cellular transport mechanisms and by
the activity of uridine phosphorylase (UPase), responsible for the reversible phosphorolysis of uridine to uracil. We have recently completed
several studies designed to define the mechanisms regulating UPase expression and better characterize the multiple biological effects of
uridine. Immunohistochemical analysis and co-purification studies have revealed the association of UPase with the cytoskeleton and the
cellular membrane. The characterization of the promoter region of UPase has indicated a direct regulation of its expression by the tumor
suppressor gene p53. The evaluation of human surgical specimens has shown elevated UPase activity in tumor tissue compared to paired
normal tissue. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction: physiological and biological role of
uridine
Pyrimidines are synthesized de novo in mammalian cells
through a multistep process starting from glutamine and
carbon dioxide to form, the pyrimidine ring in the second to
last intermediate, orotic acid, which is then converted to its
nucleotide form in the presence of PRPP. From the degra-
dation of the nucleic acids and nucleotides a large portion of
the pyrimidines are salvaged. The relative contribution of de
novo synthesis and salvage pathway to the maintenance of
the nucleotide pools varies in different cells and tissues [1].
A crucial difference between purine and pyrimidine metab-
olism is that purines are recycled from their bases while
pyrimidines are salvaged from their nucleosides, particularly
uridine. In fact, in patients with deficient pyrimidine biosyn-
thesis, only uridine is able to overcome this pathological
manifestation but uracil is not [2].
The concentration of circulating plasma uridine of
approximately 3–5 AM is tightly regulated throughout
different species and individuals [3–5]. The liver appears
to have this homeostatic control on uridine degradation and
formation [6]. Uridine is essentially cleared in a single pass
through the liver and it is replaced in a highly regulated
manner by ‘‘new uridine’’ formed by de novo synthesis [6].
We have previously reported the cellular basis for the
catabolic component of this apparent paradox by the dis-
sociation of the liver into two cell fractions, hepatocytes and
a nonparenchymal cell population. Suspensions of the non-
parenchymal cells were shown to rapidly cleave uridine to
uracil, while in hepatocytes, this activity was barely detect-
able. Conversely, hepatocytes caused extensive degradation
of uracil to h-alanine. These differences correlated with the
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uridine phosphorylase (UPase) and dihydrouracil dehydro-
genase activity present in each cell type [7].
Besides the critical role of uridine in the synthesis of
RNA and bio-membranes, through the formation of pyrimi-
dine-lipid and pyrimidine-sugar conjugates, experimental
and clinical evidence suggests a role for uridine in regulat-
ing a series of biological functions [8].
Uridine and its nucleosides have shown a complex effect
in the regulation of vascular resistance, producing opposing
effects in some tissues, either by acting directly on the
smooth muscle cells or by stimulating the surrounding
endothelial cells [9].
Uridine is present in the seminal fluid at millimolar
concentrations, a level that is approximately three orders
of magnitude higher compared to other body fluids or
tissues [10]. The presence of such a high uridine concen-
tration and its correlation with sperm motility suggests a role
of uridine in spermatogenesis [11]. Furthermore, a low level
of uridine in prostatic secretions of patients with prostatitis
also indicates a possible role of this nucleoside in the
etiology of this disease [11].
In the area of the peripheral nervous system, uridine
appears to have a modulatory role. It has been shown to
hyperpolarize amphibian ganglia and rat superior cervical
ganglia at submillimolar concentrations, possibly resulting
in an inhibitory activity [12]. Several clinical observations
indicate the crucial function of pyrimidine nucleoside sal-
vage in the maintenance of normal CNS activity [13,14]. In
the treatment of a form of autism with seizures, oral uridine
administration has led to improvement in speech, behavior
and decreased frequency in seizures [15]. Deficiencies in the
catabolism of pyrimidines due to impaired activity of one of
the steps in the catabolic pathway, such as dihydropyrimi-
dine dehydrogenase or h-ureidopropionase, have resulted in
autism, convulsions, mental retardation and decreased motor
coordination [14].
In animal models, uridine has been shown to potentiate
dopaminergic transmission and reduce anxiety [16]. Uridine
has been documented as a sleep-inducing factor in rats and
shown to increase the activity of barbiturates [17,18]. In
mice and rats, high doses of uridine cause a dramatic
reduction in body temperature [19]; whereas uridine induces
fever in human and rabbits [20,21]. The co-administration
of an inhibitor of UPase, benzylacyclouridine (BAU),
almost completely prevented the effect on thermoregulation,
suggesting that a pyrimidine catabolite, possibly h-alanine,
could alter the control of the body temperature [21].
Aside from the ‘physiological’ effects that we have just
briefly outlined, uridine appears to have remarkable func-
tions in tissues under stress or pathological situations and in
the clinical setting. In hearts subjected to ischemia, perfu-
sion with uridine rapidly restored myocardial ATP levels,
glycogen and UDPG [22]. Similarly, uridine perfusion
resulted in the maintenance of brain metabolism during
ischemia or severe hypoglycemia [23,24]. Furthermore,
uridine induced recovery from neuronal degeneration pro-
duced by diabetic neuropathy [25]. Uridine has been used as
a ‘rescue’ agent in cancer therapy to decrease bone marrow
and gastrointestinal toxicity, following 5-fluorouracil-based
drug regimens [4,26–31]. In combination with BAU, uri-
dine has shown some activity in reducing neurotoxicity and
the effects on the bone marrow of AZT during treatment for
HIV infections [32].
1.1. Role of UPase on the pharmacological activity of
uridine
Plasma and intracellular concentrations of uridine are
regulated by the catabolic activity of UPase and by two
transport mechanisms, facilitated diffusion and Na + -de-
pendent active transport. UPase catalyzes the reversible
phosphorolysis of uridine and to a lesser degree of thymi-
dine. It also cleaves pyrimidine 2V- and 5V-deoxyribosides at
a much lower rate [33–37]. UPase is present in most tissues
and in tumors, where its activity is generally elevated
[33,35,38]. The mammalian enzyme appears to be a tetra-
meric protein with subunits of approximately 33,000 molec-
ular weight. Initial velocity and product inhibition studies
suggest an ordered bi–bi mechanism where Pi binds first
before uridine and ribose-1-phosphate is released after uracil
[39]. UPase plays an important role in the homeostatic
regulation of uridine concentration in plasma and tissues
[22–25] as well as affects activation and catabolism of
fluoropyrimidines influencing their therapeutic capacity
[40–43]. The expression of UPase has been shown to be
induced in different tumor cell lines, such as Colon 26 and
HCT-116, when in the presence of cytokines: TNF-a, IL-1a
and IFN-a and g, and vitamin D3 [44–46]. A similar
response to cytokines has been observed for thymidine
phosphorylase (TPase) [47]. Induction of UPase expression
has also been reported in c-H-ras transformed NIH 3T3 cells
[48]. In a murine model, hepatic UPase has been found to
follow a circadian rhythm which was the inverse of that for
plasma uridine concentration, re-emphasizing its role in the
regulation of blood uridine level and suggesting its possible
involvement in the humoral control of sleep [49].
A misconception surrounds the role of UPase and TPase.
Some literature reports UPase as the pyrimidine nucleoside
phosphorylase in murine tissues and TPase the main phos-
phorolytic enzyme in human tissues [50]. UPase, however,
has been shown to be present in all human tissues and
tumors, whereas TPase activity has been found reduced or
absent in many human tumors [4,17,26,27,33,35,40,51–54].
1.2. ‘‘Rescue’’ of 5-fluorouracil toxicity
As previously mentioned, UPase has a critical role in
regulating the concentration of uridine in plasma and
tissues. A number of clinical studies have demonstrated
the ability of uridine to reduce 5-FU toxicity, without
affecting its antitumor activity, if properly administered
18–24 h following the cytotoxic agent [26–29].
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The combination ‘rescue regimens’ of 5-FU plus uridine
were initially proposed to evaluate the hypothesis that the
antitumor effect of 5-FU is primarily due to the inhibition of
thymidylate synthase and the host toxicity caused by the
incorporation of the fluoropyrimidine into RNA [55]. In
vivo studies in a murine model [56] and in vitro data [57]
have clearly indicated that the incorporation of 5-FU into
RNA appears to be the major cause of gastrointestinal
toxicity. Results show that uridine inhibited the incorpora-
tion and avoided the cytotoxic effect, whereas thymidine did
not prevent 5-FU toxicity. Furthermore, a recent study has
indicated that the p53-dependent apoptosis induced by 5-FU
in intestinal cells was reduced by uridine administration but
not by thymidine [58].
Because of its low oral bioavailability and a rapid half-
life, large doses of uridine are necessary to achieve clinically
relevant concentrations in plasma causing moderate to
severe toxicity including severe diarrhea as dose-limiting
toxicity [4,20]. On the other hand, infusion of uridine has
resulted in fevers, phlebitis, cellulitis, superior vena cava
syndrome, torpor and confusion, and precluded an extensive
clinical use [20,59]. Nevertheless, clinical studies of 5-FU in
combination with methotrexate and PALA, have shown that
patients tolerated combination therapy with delayed uridine
(infused over a 72-h period starting 2 h after 5-FU admin-
istration, 3 h on and 3 h off ) up to a weekly dose of 750 mg/
m2 of 5-FU, with 25% experiencing moderate mucositis
(grade II). In a previous clinical trial without uridine, four
out of six patients could not tolerate a 600 mg/m2 dose of 5-
FU because of mucositis, diarrhea and a decrease in per-
formance status. In another study, 5-FU treatment could be
continued with delayed administration of uridine at a
weekly dose of 5-FU, which alone caused dose-limiting
myelosuppression. In most of the patients who had previ-
ously developed leukopenia, the WBC increased markedly
despite continued 5-FU administration [59]. In a more
recent study of high-dose 5-FU with doxorubicin, high-dose
methotrexate and leucovorin, oral uridine administration
allowed for dose intensification of 5-FU with a 33%
increase in the MTD of 5-FU in the presence of doxorubicin
and a 45% increase in 5-FU MTD without doxorubicin [60].
No responses were obtained in patients with gastric cancer
(0/11) when uridine was administered 2 h after 5-FU,
however 2/3 patients responded with the 24-h uridine delay.
This last regimen, with a 24-h interval between the admin-
istration of 5-FU and uridine, ensured rescue from 5-FU-
induced hematologic toxicity without adverse impact on
tumor response [60]. As indicated in pre-clinical studies,
properly delayed uridine rescue results in a faster clearance
of 5-FU from RNA of bone marrow and tumors and
enhancement of the rate of recovery of DNA synthesis only
in the bone marrow [37].
Our laboratory has shown that the problem of a rapid
disposition of uridine and the administration of large doses
of the nucleoside could be overcome by utilizing inhibitors
of UPase, such as BAU, to conserve endogenous uridine
with consequent elevation of its concentration in plasma and
tissues. This approach has resulted in the reduction in
animal models of host toxicity, while maintaining the
antineoplastic effect of 5-FU [34]. A phase I clinical trial
of oral BAU administered as a single agent has shown the
ability of this inhibitor to elevate 2–3-fold the plasma
uridine concentration with no significant host toxicity in
patients [3].
1.3. Tri-O-acetyluridine (TAU)
A new agent 2V,3V,5V-tri-O-acetyluridine (TAU; PN 401)
has been tested recently in a clinical trial to rescue 5-FU
toxicity. TAU is a uridine pro-drug, the presence of the
acetyl groups increases the hydrophobicity, therefore
enhancing the gastrointestinal transport and bioavailability,
and protecting this agent from the catabolism by UPase.
Uridine is then progressively released by plasma esterases
resulting in sustained delivery over time without most of the
side effects of uridine administration. The sustained elevated
level of uridine, up to 50 AM in plasma, has allowed a dose
escalation of 5-FU, administered as a rapid intravenous
bolus weekly for 6 weeks, from 600 to 1000 mg/m2. Still,
an oral dose of 6 g of TAU at 6-h intervals was necessary to
produce significant uridine levels [61].
2. Regulation of uridine homeostasis: transport
mechanisms
Besides catabolism by nucleoside phosphorylase activity,
the intracellular concentration of uridine is regulated by its
transport through the cell membranes. A facilitated-diffu-
sion mechanism, which equilibrates intracellular and extrac-
ellular uridine, has been considered for many years to be
responsible for intracellular uridine concentration. This non-
energy dependent process displays broad substrate specific-
ity toward synthetic and naturally occurring pyrimidine
nucleosides [62–65]. In addition to competition between
functional substrates, the facilitated diffusion of nucleosides
present in most cell lines can be reversibly inhibited by
compounds such as dipyridamole and nitrobenzylthioino-
sine [66]. Studies by Belt [67,68] have revealed that the
facilitated diffusion mechanism in cell lines can be distin-
guished by the sensitivity to inhibition by NBMPR or
dipyridamole. Recently, both transporters, NBMPR-sensi-
tive (es) and NBMPR-insensitive (ei) have been cloned and
characterized [69,70].
In addition to the non-concentrative facilitated diffusion
mechanism, renal and gut epithelial cells were shown to
possess a Na + -dependent transporter for nucleosides [71–
77]. Our laboratory revealed the potential physiological
significance of this Na + -dependent transport system by
the finding that concentrations of uridine in a variety of
freeze-clamped normal murine tissues far exceeded the
concentration of uridine in the plasma. We were able to
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demonstrate that BAU generated concentrations of uridine
in selected tissues that were as much as 50–100 times that
in control plasma [34]. The concentrative system in liver,
kidney and gut appears to have different substrate specificity
than in lymphoid cells (spleen or thymus). In addition, we
have demonstrated the generality of the expression of a
concentrative, active transport mechanism for uridine in a
variety of normal murine tissues [53]. These observations
changed the perception of the Na + -dependent uridine trans-
port process from a rate phenomenon observed in isolated
cells to a major physiological effect that afforded therapeutic
opportunities considering that the intracellular concentra-
tions of uridine in a wide variety of neoplastic cell lines did
not exceed those in the media. It has been shown that some
lines express the concentrative mechanism to a very limited
degree [78] but that it is overwhelmed by the equilibration
of nucleoside achieved by an active facilitated diffusion
mechanism. At this moment, five major Na + -dependent
active transport systems have been isolated: (1) the purine
selective N1 system, or cif, shown to be present in rat
intestinal epithelium, mouse enterocytes and lately in human
kidney [79–82]; (2) the pyrimidine selective N2 system or
cit described by Jarvis and Griffith [83], present in rabbit
small intestine with selectivity for pyrimidine nucleosides
and adenosine; (3) the N3 transport system (cib) isolated in
rat jejunum sensitive to inhibition by both purine and
pyrimidines [84]; (4) the N4 transport system, expressed
in human kidneys, which is identical to the N2 system in
substrate specificity [85]; and the N5, a cs transport system,
found in freshly isolated human leukemia cells [86].
3. UPase: clinical, biological and regulation update
Over the past few years, we have focused on the role of
UPase in regulating uridine metabolism and its intracellular
levels in normal and neoplastic tissues and on the mecha-
nisms controlling the expression and localization of UPase.
We have determined that the activity of UPase is elevated in
tumors as compared to their normal tissue counterpart and
discovered variant uridine phosphorolytic activity in
selected human tumors [54]. We have also defined the
genomic structure of the UPase gene, characterized its
promoter region, the p53-dependent control of its expression
[87,88] and established its intracellular localization and
association with cytoskeletal elements [89].
3.1. Expression and detection of UPase and identification of
variant phosphorolytic activity in human tumors
TPase catalyzes the reversible phosphorolysis of thymi-
dine to thymine and with less efficiency also contributes to
the initial degradation of uridine. Since TPase has been
shown to be identical to platelet-derived endothelial cell
growth factor (PD-ECGF) and its angiogenic activity dem-
onstrated [90,91], several studies have investigated the role
of this protein in tumor progression and clinical outcome.
Increased expression has been found in some solid tumors
compared to the adjacent normal tissues [92] and TPase has
been shown to be a negative prognostic indicator in bladder
[93], colo-rectal [94,95], ovarian [92], pancreatic [96] and
renal [97] cancers but its role is still controversial in breast
carcinoma [98,99]. PD-ECGF/TPase has been shown to
promote angiogenesis only when enzymatically active and
in the presence of thymidine [100].
The intense investigation of the role of TPase on cancer
invasiveness and malignancy has not translated to a similar
interest for a potential involvement of UPase, despite its
complementary phosphorolytic activity.
We have evaluated the activity of UPase in fresh tumor
specimens and adjacent normal tissues of patients undergoing
surgical resection of their malignancy. The enzymatic activity
was variable among the different tissue specimens, but over-
all it was 2–3-fold higher in tumors compared with the paired
normal tissue (Fig. 1). In the tissues that we were able to
collect the most clinical specimens, breast (n = 28) and colon
(n = 9) carcinomas, the difference in activity between tumor
and normal tissues was statistically significant with P values
of 0.012 and 0.021, respectively [54]. These results have been
confirmed in a recent study in 35 human colo-rectal carcino-
mas also indicating higher UPase mRNA gene expression in
tumor compared to paired normal tissue [101]. The same
study concluded that higher UPase gene expression was a
negative prognostic factor for the patient [101]. In all normal
tissues and most tumor specimens evaluated in our inves-
tigation [54], UPase activity was completely inhibited by the
UPase inhibitor BAU at 10 AM concentration. However,
breast, head-neck, and ovarian tumors showed partial sensi-
tivity to the inhibitor withf 40% of residual phosphorolytic
activity still present after the addition of 100 AMBAU. Using
the TPase inhibitor 5-bromo-6-aminouracil [102], we were
able to establish that TPase does not significantly contribute
to the BAU insensitive phosphorolytic activity present in
breast tumor tissue.
The evaluation of the clinical specimens has clearly
indicated that normal tissues like gastrointestinal tract and
bone marrow, that are the most sensitive to fluoropyrimidine
toxicity, possess UPase activity completely inhibitable by
BAU. However, human breast tumors possess distinct
phosphorolytic activity that is partially insensitive to the
classical UPase inhibitors, therefore resulting in a more
rapid degradation of uridine. This differential catabolism
of the pyrimidine nucleoside could be exploited to create, in
the presence of BAU, a selective rescue effect for normal
tissues without affecting the antineoplastic activity in breast
neoplastic tissues therefore enhancing the therapeutic index
of the fluoropyrimidine.
Our study, on human clinical specimens revealing the
presence of higher UPase enzymatic activity in tumor
tissues as compared to paired normal tissue is in contrast
with a previous report from Maehara et al. [48] indicating no
difference in UPase activity between tumor and normal
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tissues. We also disagree with another finding from the same
group indicating that the main pyrimidine nucleoside phos-
phorylase in human is TPase with activity 20-fold higher
than UPase [48]. In our evaluation, we have observed a
degree of variation in the ratio of TPase to UPase activity in
human tissues with an overall ratio of 2. However, in many
tissues including breast tumors, the ratio was actually in
favor of UPase. Our investigation has also indicated that
both bone marrow and gut mucosa specimens possess low
phosphorolytic activity compared to tumor tissues, suggest-
ing that uridine rescue could specifically benefit these
tissues representing the primary targets of 5-fluorouracil
toxicity, as reported by Pritchard et al. [58] in a study on its
effect on the intestinal mucosa.
A recent article from Kanzaki et al. [103] has examined
the mRNA expression of UPase and TPase in surgical
specimens of 43 patients with breast carcinoma and exam-
ined the correlation with clinical pathological factors. The
investigators have found a large variation in the expression
level of both genes with the highest level measured as more
than 1000-fold higher than that in samples expressing the
lowest level. There was a significant correlation between
TPase expression and microvessel density but no correlation
with UPase expression suggesting that UPase does not have
any angiogenic activity in human breast carcinoma. In
addition, no correlation was found between UPase gene
expression and TPase expression level in those breast tumor
samples. However, UPase gene expression was higher in
patients who relapsed than in patients that did not and
patients with high UPase mRNA levels had a significantly
poorer overall survival than patients with lower levels.
TPase gene expression did not correlate with either relapse
or overall survival in these breast cancer patients [103]. This
critical study confirms a previous study from the same
group indicating a lack of correlation between clinical
outcome and TPase mRNA expression in breast cancer
[98]. However, it suggests that UPase could be an inde-
pendent prognostic factor in breast cancer patients [103].
3.2. UPase genomic structure, characterization of its
promoter region and p53-dependent control of its expres-
sion
We have recently isolated from a murine BAC library a
genomic DNA fragment which included the entire murine
UPase gene, whose full length approximates 18.0 kb. The
UPase gene has been mapped by FISH to the murine
chromosome 11A1–2. A series of oligonucleotide primers
based on the cDNA sequence of murine UPase have been
utilized to elucidate the intron–exon boundaries [87]. Our
results indicate that the murine UPase gene consists of nine
exons, ranging in length from 66 to 210 bp, and eight
introns varying in size from 240 to 6.0 kb, with typical
donor and acceptor sites (GT-AG rule). Exon 1, 2 and the
5Vend part of exon 3 do not encode amino acids, the first in-
frame ATG codon is located in exon 3. Exon 8 encodes the
C-terminus of murine UPase protein and contains a trans-
lation stop codon TGA. It also contains the first 70 bp of the
3V-untranslated region. A polyadenylation signal, AATAAA,
is present at 45 bp downstream of the TGA codon [87]. We
have now also concluded the characterization of the human
UPase gene that presents the same basic structure with nine
Fig. 1. UPase activity in matched pairs of human breast tumor and normal tissues following surgical excision of the malignancy.
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exons and eight introns. Chromosomal mapping of human
UPase identified its location at 7p12, a position where
frequent LOH has been found in human breast cancers
[104].
The sequence of the 3V-untranslated flanking region of
the murine UPase gene shows a GT-rich region present 22
bp downstream of the AATAAA polyadenylation signal. A
TGGGG tandem repeat, TGGGGG(TGGGG)4, is present at
154 bp downstream of AATAAA polyadenylation signal,
which represents a putative recombination consensus
sequence found in the immunoglobulin switch region (S
region), in the a-globin gene cluster, in the putative arrest
sites for polymerase a, and in the deletion hot spot (exon 8)
of the survival motor-neuron (SMN) gene [105–107].
The 5Vflanking region of the murine UPase gene, the
immediate full-length sequence (1703 bp) that has shown
promoter activity in our studies, doesn’t contain canonical
CAAT box although a TATA-like sequence, CAATAAAA,
is present from  41 to  49 bp upstream of the tran-
scription start point at + 1 bp. The lack of both canonical
TATA and CAAT consensus sequences is a feature present
in a group of genes, many of which have a housekeeping
function, such as N-ras and transforming growth factor a
[108]. At the 5Vend of UPase promoter (from  1619 to
 1110) we identified a series of microsatellite and minis-
atellite repeat bases. In addition, an abundance of promoter
regulatory elements are seen in the murine UPase promoter
region including the presence of the consensus motifs for
GATA-1 and two transcription factors. These factors mainly
function as regulatory elements in the control of cellular
differentiation of hematopoietic cells [109,110]. An IRF-1-
like consensus element present just upstream (from  21 to
 33) of the putative transcription start site of the UPase
gene represents an important transcription factor in the
regulation of the interferon response system for infection,
cell growth and apoptosis [111,112]. Finally, two potential
proto-oncogene binding sites for C-Myb and V-Myb [113–
115], and a tumor suppressor gene, p53 putative regulatory
element [116–118], located in the sequence  303 bp to
 294 bp, have been found in the UPase promoter region.
To explore the possible effect of p53 on UPase expres-
sion, we have analyzed the effects of p53 on the murine
UPase promoter activity [88]. We found that the deletion
from  1619 to  445 of the UPase promoter had no effect
on the ability of p53 to inhibit gene expression, however, the
inhibitory activity was altered when the promoter region
between  445 and  274 bp was deleted. Using transient-
expression assays in EMT6 and NIH 3T3 cells, co-trans-
fection with the wild-type p53 construct resulted in signifi-
cantly less luciferase activity in the constructs from  1619
to  445 bp, whereas down to  274 bp and more, the
promoter activity was not affected. These data indicate that
the region between  445 and  274 bp is susceptible to
regulation by p53 in the UPase promoter. This phenomenon
was further confirmed in p53 nullified cells [88]. Sequenc-
ing analysis of this region found a putative p53-binding
motif AGcCTTGTCC located at  303 to  294. This
binding motif differs in one base (small case base) from
the consensus binding element of p53 [119]. The gel
mobility shift assay and DNase I footprinting have indicated
that this putative regulatory motif exhibited specific binding
with the p53 protein [88].
p53 has been shown, by Linke et al. [120], to be
activated by ribonucleotide depletion caused by antimeta-
bolite drugs such as PALA even in the absence of DNA
damage. As previously mentioned, the phosphorolytic activ-
ity of UPase regulating intracellular uridine levels reveals
the critical role of this enzyme in modulating the pyrimidine
salvage pathway. The suppressive regulation of p53 on
UPase gene indicates the presence of a negative control of
the pyrimidine salvage pathway by p53 through UPase,
probably as a cellular self-protection mechanism in case of
ribonucleotide depletion. p53 has previously been shown to:
(a) activate genes that initiate apoptosis to eliminate dam-
aged cells and protect an organism from more severe
damage and (b) cause cell-cycle arrest following DNA
damage to prevent the replication of altered DNA. However,
so far, any indication of the contribution of p53 to damage
repair is quite limited. A recent report by Tanaka et al. [121]
has described a p53-induced gene, p53R2 that encodes for a
protein similar to one of the two subunits of ribonucleotide
reductase, the rate-limiting step in the conversion of ribo-
nucleotides to deoxyribonucleotides. The p53 regulated R2
subunit is found in the nucleus and its expression is induced
by cellular damage (g-radiation and doxorubicin treatment)
suggesting that when repair is needed, the nuclear precur-
sors have to be concentrated near the site of damage.
Somehow, the p53-regulated suppression of UPase
expression exerts similar functions to the control that p53
has on p53R2. A cellular damage causing loss or imbalance
in the ribonucleotide pools could cause activation of p53
leading to suppression of UPase expression and activation
of the pyrimidine salvage pathway to replenish the affected
pyrimidine nucleotide pools (Fig. 2). These two p53-regu-
Fig. 2. p53-dependent control of UPase expression and regulation of py-
rimidine salvage pathway following PALA inhibition of de novo pyrimi-
dine biosynthesis.
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lated mechanisms provide a new level of control on ribo-
and deoxy-ribonucleotide pools. Under normal replication
conditions, the regulating mechanisms that control the
appropriate balance of nucleotides are mostly based on the
direct feedback regulation of the biosynthetic enzymes by
some of the precursors or final products. However, the
p53R2 study and our data on UPase possibly indicate that
in case of cellular damage with depletion of nucleotide
pools a more sophisticated level of regulation is triggered to
more rapidly provide precursors for nuclear repair [88,121].
The elucidation of the negative control regulation of p53
on the UPase gene promoter and UPase expression could
also have considerable implication at the clinical level since
the human UPase DNA promoter presents, as we have
shown for the murine gene, a p53 regulatory element [88].
It is conceivable that mutations and loss of functionality of
the p53 gene product, which is a common event in many
forms of cancer [122], could alter the suppressive regulatory
control on UPase resulting in higher UPase mRNA expres-
sion and elevated UPase activity seen in many tumors as
compared to paired normal tissues [54].
3.3. Intracellular distribution, localization and association
with vimentin
We have established that UPase is associated with the
intermediate filament vimentin in NIH 3T3 fibroblasts and
Colon 26 cells through co-purification studies using a 5V-
amino benzylacyclouridine affinity matrix. The separation
of cytosolic proteins using gel filtration chromatography
yields a high molecular weight complex containing UPase
and vimentin in a 1:1 stoichiometry. Immunofluorescent
techniques have confirmed that UPase is associated with
vimentin and that the depolymerization of the microtubule
system using nocodazole results in UPase remaining asso-
ciated with the collapsed intermediate filament, vimentin
[89].
UPase is associated with both the soluble pool of vimentin
and also with its insoluble pool, with approximately 50–70%
of the total UPase present in the cytosol as a soluble protein.
However, sequential cell extraction liberates an additional
15–25% UPase activity associated with a Triton-X-100
soluble fraction and a remaining 10–20% UPase activity
associated with a Triton-X-100 insoluble pool [89].
The role of UPase in the salvage pathway of pyrimidine
nucleoside biosynthesis does not readily translate into a role
for this enzyme in association with the cytoskeleton and
more specifically with the intermediate filament vimentin.
While a number of theories have been proposed for the
function of this network, the data are not yet conclusive.
Cellular processes as diverse as differentiation, motility,
signal transduction, cell division, cytoskeletal stability and
vesicular trafficking have been associated with alterations in
the dynamics of the intermediate filaments [123–127].
A number of proteins have been shown to be associated
with the vimentin intermediate filament scaffold including
p53 [128], protein kinase C [129], Yes and cGMP kinase
[130,131], glycolytic enzymes creatine phosphokinase and
GAPDH [132–134] and nucleoside diphosphate kinase
[132,135] as well as the cross-linking proteins plectin,
IFAP-300 and filamin that link intermediate filaments to
other cytoskeletal elements and membranes [136–139]. It is
particularly interesting to note the number of proteins
involved in signal transduction and energy metabolism that
have been associated with vimentin. The proposed role for
NDPK in nucleotide channeling [135], its co-purification
with vimentin and enzymes involved in ATP formation/
regeneration [132] together with our observation of UPase
co-localization with this same cellular machinery, is making
it more likely that such observations are biologically rele-
vant. UPase, a nucleoside phosphorylase and NDPK, an
enzyme that provides the majority of cellular non-ATP
nucleoside triphosphates have both been co-localized to
the intermediate filament vimentin. Since a number of
biological responses have been associated with UTP and
UDP [140] through the activation of pyrimidine receptors, it
is possible that vimentin may play a role in the coordination
of these signaling events.
In vitro enzymatic analyses of the detergent-resistant
pool of UPase demonstrated that this source of enzyme
retains enzymatic activity. The UPase found in association
with the polymeric vimentin network may represent a
mobilizable pool of enzyme that is only active when
liberated from its three-dimensional network. It is also
possible that UPase, in association with the insoluble
vimentin network, represents a way of localizing enzymatic
activity to a particular area within the cell. Vimentin has
been proposed as a network that might target mRNA to
areas of active protein synthesis [124]. This function for
vimentin might explain the necessity of having machinery
for pyrimidine synthesis/degradation in close proximity to
areas of mRNA translation.
The interdependence of the dynein and kinesin motor
proteins, microtubule and intermediate filament systems and
the need to furnish this cellular machinery with high
quantities of nucleotide triphosphates provides a basis for
investigating the mechanisms responsible for the local
delivery of high quantities of NTPs to the areas of active
energy utilization. The question of what role UPase may
play in close proximity to such machinery is at this moment
cause for speculation.
4. Conclusions
Many factors have contributed to the limited attention
uridine and UPase have received despite their physiologic
and pharmacological role in comparison to the interest
reserved over the years to adenosine and TPase.
Adenosine has been shown to have a general inhibitory
effect on neuronal activity including regulation of sleep,
neuroprotection and seizure control [141]. Furthermore, this
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purine nucleoside appears to have cardioprotective and
immunomodulatory functions [142]. These regulatory and
modulatory activities of adenosine are mediated by four
subtypes of G-protein-coupled receptors [143]. As we have
indicated in our introduction, uridine exerts very similar
modulatory and regulatory functions to adenosine, however,
no clear mechanism has been identified modulating these
physiological activities. Receptors for uridine nucleotides
have been mentioned and also the possible existence of a
specific receptor for uridine itself has been postulated. A
very recent report suggests the presence of a new receptor
identified as ‘‘uridine receptor’’ regulating the hypnotic
activity of uridine derivatives in rat brain [144]. More
studies are needed to confirm this finding, to elucidate the
biological and structural characteristic of the receptor, and
the interactions with other receptors and substrates. It is
critical to extend these studies to other organs to determine
the presence of ‘‘uridine receptor(s)’’ not only in the central
nervous system but also in the cardio-circulatory system and
at the reproduction level. These studies will lead to the
discovery of a new interacting molecules and the develop-
ment of new class of therapeutic agents for various human
diseases.
Similarly, the attention dedicated to TPase is associated
to its angiogenic properties [144] and more recently, to its
link to a human genetic disease, MNGIE [145], and it could
be matched by UPase only after we have better defined its
physiological function and its possible role in human dis-
eases. Our discoveries of an elevated expression of UPase in
human tumors [54], its altered pattern of inhibition in breast
cancers [54] and the intracellular association with the
cytoskeleton [89] only represent starting points to gain
new insight in its biological functions and define its clin-
ical–pathological role.
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